Scalper1 News
Biotechs have not only shown resilience during bouts of volatility the past few months but they also remain a top group with many leading stocks setting up in bases. On Tuesday, biotech startupJuno Therapeutics (JUNO) soared 15% in heavy trading following its late Monday announcement of a $1 billion deal with Celgene (CELG). Celgene will pay $150 million upfront and buy 9.1 million Juno shares for 93 each, or $850 million, for the option to Scalper1 News
Scalper1 News